William John Sibold

President and CEO. Files against MDGL. Everything below is filed with the SEC within two business days of the trade. Filed as Sibold William John.

Filed lines

2026-07-17 to 2026-09-11

Bought

—

open market

Sold

$7.6M

open market

Net

$7.6M

sold more

Every reported line

Purchases, sales, grants, option exercises and shares withheld for tax.

Company	Action	Shares	Price	Value	Date
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	60	$533.09	$32K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	106	$534.06	$56.6K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	218	$535.94	$116.8K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	160	$537.62	$86K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	687	$540.59	$371.4K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	368	$541.64	$199.3K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	1.2K	$542.60	$652.2K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	1.5K	$544.02	$837.3K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	761	$544.83	$414.6K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-11	Sale10b5-1 plan	120	$546.38	$65.6K	2026-09-11
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	215	$539.03	$115.9K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	505	$540.19	$272.8K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	362	$541.65	$196.1K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	160	$542.55	$86.8K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	131	$527.88	$69.2K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	347	$529.27	$183.7K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	522	$530.23	$276.8K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	368	$531.99	$195.8K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	512	$533.09	$272.9K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	396	$534.20	$211.5K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	644	$535.27	$344.7K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	1K	$536.11	$557.6K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	640	$537.17	$343.8K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-09-09	Sale10b5-1 plan	520	$538.30	$279.9K	2026-09-09
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	280	$555.05	$155.4K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	140	$542.75	$76K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	110	$543.79	$59.8K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	545	$544.71	$296.9K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	275	$545.71	$150.1K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	269	$547.08	$147.2K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	680	$547.70	$372.4K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	47	$548.87	$25.8K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	153	$550.01	$84.2K	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-20	Sale	1	$550.72	$550.7	2026-07-20
MDGLMadrigal Pharmaceuticals Inc2026-07-17	Option exercisederivative	50K	—	—	2026-07-17
MDGLMadrigal Pharmaceuticals Inc2026-07-17	Option exercise	50K	—	—	2026-07-17

Source: SEC Form 4 and Form 144 filings, via EDGAR. Form 144 carries no filer identifier, so those notices are matched to this page by name alone. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.

Follow William John Sibold by email

William John Sibold's new Form 4 trades, with the rest of the week's filings. One email a week, free.

Unsubscribe with one click from any email.

Related datasets

PeopleCEOs, investors, public officials and market commentators.SEC FilingsAuditor changes, restatements, departures and results, from 8-Ks.Insider TradingWhat company officers and directors buy and sell.Insider BuyingCluster buys, and chief executives buying their own stock.